NDC 76329-8261-01 - Lorazepam
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 76329-8261
- Requested NDC
- 76329-8261-01
- Package NDCs from labels
- 76329-8261-1, 76329-8261-01
- Manufacturer
- REMEDYREPACK INC.
- Effective date
- 2024-03-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Lorazepam - REMEDYREPACK INC. | REMEDYREPACK INC. | 2024-03-14 | HUMAN PRESCRIPTION DRUG LABEL |
| Lorazepam - International Medication Systems, Limited | International Medication Systems, Limited | 2024-03-04 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 76329-8261-1 | Lorazepam | 10 mL in 1 VIAL | INJECTION | 10 | 13 | |
| 76329-8261-1 | Lorazepam | 10 in 1 CARTON | INJECTION | 10 | 13 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 76329-8261 | LORAZEPAM INJECTION [INTERNATIONAL MEDICATION SYSTEMS, LIMITED ] | 13 | Current NDC, Legacy NDC, 2 package rows | 20240306_7dda070d-7809-46c4-8592-eb4e4c509707.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 76329-8261-1 | ML - Milliliter | 76329-8261 | 434a2601-7460-488b-b472-386a13aa9343 | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Lorazepam | ACTIVE INGREDIENT | O26FZP769L | LORAZEPAM INJECTION [INTERNATIONAL MEDICATION SYSTEMS, LIMITED ] | 2 | |
| Lorazepam | ACTIVE MOIETY | O26FZP769L | LORAZEPAM INJECTION [INTERNATIONAL MEDICATION SYSTEMS, LIMITED ] | 2 | |
| Benzyl Alcohol | INACTIVE INGREDIENT | LKG8494WBH | LORAZEPAM INJECTION [INTERNATIONAL MEDICATION SYSTEMS, LIMITED ] | 2 | |
| Polyethylene glycol 400 | INACTIVE INGREDIENT | B697894SGQ | LORAZEPAM INJECTION [INTERNATIONAL MEDICATION SYSTEMS, LIMITED ] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Retaine Ultra PF | POLYETHYLENE GLYCOL | OCuSOFT LLC | a5aaaf06-772d-44d3-8601-f978ddc48ad7 | 2026-04-13 | Warnings | B697894SGQ |
| Crocodile Tears Lubricant Eye Drops | GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 | Crocodile Tears LLC | 4df29336-ea0c-0484-e063-6294a90a685a | 2026-03-26 | Warnings | B697894SGQ |
| Artificial Tears Lubricant Eye Drops | GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400 | KC Pharmaceuticals, Inc | 4de5c844-85ca-ff9f-e063-6394a90ac12c | 2026-03-25 | Warnings | B697894SGQ |
| BLINK TRIPLE CARE | POLYETHYLENE GLYCOL 400 | Bausch & Lomb Incorporated | a2b34eb0-001b-4f42-a8cc-c2a0150fafcc | 2026-03-20 | Warnings | B697894SGQ |
| Lorazepam | LORAZEPAM | Fresenius Kabi USA, LLC | 462a13da-259a-40e7-bd5b-f7f42ae025b7 | 2026-03-13 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Leader Ultra Lubricating Eye Drops | POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL | Cardinal Health | d7f011a2-05ba-47c3-9519-d31602e105c7 | 2026-03-12 | Warnings | B697894SGQ |
| Leader Advanced Relief Eye Drops | DEXTRAN 70, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Cardinal Health | 5c5d6c13-9b51-48f0-8627-b60b0f707fd3 | 2026-03-12 | Warnings | B697894SGQ |
| Artificial Tears | GLYCERIN | Preferred Pharmaceuticals Inc. | dd646c72-8f47-43c6-a734-db0dcc8cd4d1 | 2026-03-06 | Warnings | B697894SGQ |
| Walgreens Unscented Pain Relieving | LIDOCAINE HYDROCHLORIDE, BENZYL ALCOHOL | Walgreen Co. | 41eadb4f-2ca5-42a1-e063-6294a90ab4e2 | 2026-03-04 | Warnings | LKG8494WBH |
| LORAZEPAM | LORAZEPAM | PD-Rx Pharmaceuticals, Inc. | 0418ad09-3069-4381-9a8f-e41b234fdac6 | 2026-02-26 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| GoodSense Eye Drops Advanced Relief Moisturizer | DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Sportpharm LLC | 8d58dcbb-72a0-41f0-9eeb-613072a6d7ae | 2026-02-06 | Warnings | B697894SGQ |
| Lorazepam | LORAZEPAM | A-S Medication Solutions | 8361519b-be1a-4542-a782-d7cdfa153e86 | 2026-01-24 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| Lorazepam | LORAZEPAM | REMEDYREPACK INC. | a0a33933-f697-4d3b-ba99-8a995a4b6c6b | 2026-01-09 | Boxed warning, Warnings, Adverse reactions | O26FZP769L |
| LORAZEPAM | LORAZEPAM | DIRECT RX | 4832f02d-289c-2fe6-e054-00144ff8d46c | 2026-01-08 | Warnings, Adverse reactions | O26FZP769L |
| Lubricant Eye Drops Solution | POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL | AvPAK | f5743b38-e3d2-a065-e053-2995a90a4b9a | 2026-01-08 | Warnings | B697894SGQ |
| Value Health by Prodose Eye Drops | TETRAHYDROZOLINE HYDROCHLORIDE AND POLYETHYLENE GLYCOL 400 | Prodose, Inc. | 3fafa362-a8a6-3f91-e063-6394a90a98b3 | 2025-12-31 | Warnings | B697894SGQ |
| Signature Care Eye Drops High Performance | POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL | Better Living Brands LLC | 6f1f4f58-3208-4b06-9afb-c4beeed09314 | 2025-12-30 | Warnings | B697894SGQ |
| Target Lubricant Eye Drops High Performance | POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL | Target Corporation | 6c449374-8847-4c4a-9073-1951ff31d404 | 2025-12-30 | Warnings | B697894SGQ |
| Target Lubricant Eye Drops High Performance | POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL | Target Corporation | ddc15dac-fbd8-42fa-80db-79f49fc6b9eb | 2025-12-30 | Warnings | B697894SGQ |
| CVS Advanced Eye Drops | DEXTRAN 70, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HYDROCHLORIDE | CVS Pharmacy, Inc. | f74a2fca-902c-f68a-e053-6394a90abb88 | 2025-12-30 | Warnings | B697894SGQ |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.